Namely, while survival analysis and immunohistochemistry are both consistent with literature data suggesting EMX2 as endometrial tumor suppressor, the EMX2high group of patients were found to have higher expression of CTNNB1 and FGFR2, two known oncogenes implicated in endometrial oncogenesis82. Here, FGFR2 is linked to endometrium neoplasm.